921 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $164.04 $54.56B Downtrend
Article Searches
Another February Biotech Catalyst To Watch https://seekingalpha.com/article/4143974-another-february-biotech-catalyst-watch?source=feed_sector_healthcare Feb 07, 2018 - On Jan. 31, I published an article on three biotech catalysts to watch in February; this article adds another one to the list.On Feb. 17, Apricus Biosciences will get the FDA verdict on Vitaros, a top
3 Things In Biotech You Should Learn Today: February 6, 2018 https://seekingalpha.com/article/4143855-3-things-biotech-learn-today-february-6-2018?source=feed_sector_healthcare Feb 07, 2018 - Allergan scores supplemental approval for hospital-acquired infection.Spectrum scores on efficacy in a supportive care study.AMAG Pharmaceuticals scores supplemental approval for Feraheme.
Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results https://seekingalpha.com/article/4143836-daily-pharma-scoop-nabriva-pullback-gw-pharmaceuticals-makes-progress-contravir-announces?source=feed_sector_healthcare Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.
Mayo Investment Advisers Llc Buys Schlumberger, Sells Hess Corp, Allergan PLC, Acacia ... http://www.gurufocus.com/news/636913/mayo-investment-advisers-llc-buys-schlumberger-sells-hess-corp-allergan-plc-acacia-communications-inc Feb 07, 2018 - Mayo Investment Advisers Llc Buys Schlumberger, Sells Hess Corp, Allergan PLC, Acacia Communications Inc, Stocks: SLB,HES,AGN,ACIA,GOOGL,C,AAPL,NWL,T,GPOR,CTSH,GM,G, release date:Feb 07, 2018
Wall Street Breakfast: Volatility Plagues The Markets https://seekingalpha.com/article/4143906-wall-street-breakfast-volatility-plagues-markets?source=feed Feb 07, 2018 - U.S. stock index futures dropped deep into the red again overnight, pulling back from the roller coaster ride in the previous session that saw the DJIA close up 567 points following two major selloff
Allergan: Still No Triggers, Soft 2018 Ahead https://seekingalpha.com/article/4143808-allergan-still-triggers-soft-2018-ahead?source=feed_sector_healthcare Feb 06, 2018 - Allergan ended 2017 on a solid note, but guides for declining sales in 2018.This is concerning as it takes longer for the pipeline to translate into growth as leverage remains high.While shares look c
Allergan Plc (AGN) Q4 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4143797-allergan-plc-agn-q4-2017-results-earnings-call-transcript?source=feed_sector_healthcare Feb 06, 2018 - Allergan Plc (NYSE:AGN)Q4 2017 Earnings CallFebruary 06, 2018 8:30 am ETExecutivesDaphne Karydas - Allergan PlcBrenton L. Saunders - Allergan PlcWilliam J. Meury - Allergan PlcC. David Nicholson - All
Allergan plc 2017 Q4 - Results - Earnings Call Slides https://seekingalpha.com/article/4143632-allergan-plc-2017-q4-results-earnings-call-slides?source=feed_sector_healthcare Feb 06, 2018 - The following slide deck was published by Allergan plc in conjunction with their 2017 Q4 earnings call.
Allergan (AGN) Beats Q4 Earnings & Sales, Stock Up http://www.zacks.com/stock/news/291414/allergan-agn-beats-q4-earnings-sales-stock-up?cid=CS-ZC-FT-291414 Feb 06, 2018 - Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Your Daily Pharma Scoop: AMAG Gets Label Expansion For Feraheme, Bristol-Myers Squibb Reports Results, EyeGate Shares Tumble https://seekingalpha.com/article/4143354-daily-pharma-scoop-amag-gets-label-expansion-feraheme-bristol-myers-squibb-reports-results?source=feed_sector_healthcare Feb 06, 2018 - AMAG got a nod for label expansion for Feraheme from the FDA. Bristol-Myers Squibb’s Q4 results beat expectations. EyeGate tumbles as lead candidate fails.

Pages: 12345678...93

<<<Page 3>